Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€8.20

€8.20

0.000%
-
0.000%
€17.12

€17.12

 
12.12.25 / Stuttgart Stock Exchange WKN: A2JQN1 / Symbol: REPL / Name: Replimune Group / Stock / Small Cap /
Latest predictions
€11.15
20.10.25
14.47%
buy
€11.15
20.10.25
16.00%
buy
€15.44
20.10.25
9.43%
buy
19.09.25
197.95%
30.07.25
39.20%
buy
€1.70
23.07.25
262.50%
Your prediction

Replimune Group Inc Stock

There is no change in the price for Replimune Group Inc today.
We see a rather positive sentiment for Replimune Group Inc with 13 Buy predictions and 2 Sell predictions.
With a target price of 17 € there is potential for a 107.32% increase which would mean more than doubling the current price of 8.2 € for Replimune Group Inc.
Our community identified positive and negative aspects for Replimune Group Inc stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Replimune Group Inc stock. On the other hand our users think that "Unique positioning" could be a problem in the future.

Pros and Cons of Replimune Group Inc in the next few years

Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-10-30

Eine erste Durchsicht der Finanzunterlagen der Replimune Group zeigt ein gemischtes Bild. Während einige Aspekte positiv aufgenommen werden können, deuten andere auf mögliche Herausforderungen hin, die das Unternehmen in Zukunft bewältigen muss.

Beginnen wir mit den Vorteilen in der Finanzsituation der Replimune Group. Das Unternehmen verfügt über ein beachtliches Kapital von 555 Millionen US-Dollar (Stand 2023), was bedeutet, dass es über ausreichende Ressourcen verfügt, um seine aktuellen Geschäftsaktivitäten zu unterstützen. Außerdem ist erfreulich, dass die Aktien des Unternehmens relativ stabil geblieben sind, mit einer geringen Änderung im Jahr, was auf eine stabile Anlegerbasis hindeutet.

Darüber hinaus verfügt die Replimune Group über eine erhebliche Menge an kurzfristigen Investitionen (436 Millionen US-Dollar) im Jahr 2023. Diese können in bar umgewandelt werden, falls das Unternehmen Liquidität benötigt, was seine finanzielle Flexibilität erheblich verbessert.

Comments

Prediction Buy
Perf. (%) 14.47%
Target price 11.149
Change
Ends at 20.10.26

Replimune Group (NASDAQ:REPL) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $13.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 16.00%
Target price 11.149
Change
Ends at 20.10.26

Replimune Group (NASDAQ:REPL) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $13.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 9.43%
Target price 15.437
Change
Ends at 20.10.26

Replimune Group (NASDAQ:REPL) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $18.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Show more

News

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune


Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) and reminds investors of